Methods useful in the treatment of bone resorption diseases
AssigneeNPS Allelix Corp.
InventorsJohn Dietrich, Sverker Ljunghall, Sven Sjögren
Life of this patent
Estimating the term…
Abstract
The invention relates to a combined pharmaceutical preparation comprising parathyroid hormone and a bone resorption inhibitor, said preparation being adapted for (a) the administration of parathyroid hormone during a period of approximately 6 to 24 months; (b) after the administration of parathyroid hormone has been terminated, the administration of a bone resorption inhibitor during a period of approximately 12 to 36 months.
Claims16
A method for enhancing bone mineral density in a human needing enhancement of bone density, consisting essentially of administering to said human a human PTH (1-84) pharmaceutical formulation, having a single active agent consisting of a human PTH (1-84), and is administered once daily at a PTH (1-84) dose of 50–100 μg.
A method for treating a post menopausal female human afflicted with osteoporosis to enhance bone mineral density of said human consisting essentially of administering to said human a human PTH (1-84) pharmaceutical formulation, having a single active agent consisting of a human PTH (1-84), and is administered to said human by subcutaneous injection once daily at a PTH (1-84) dose of 100 μg for a period of 12 months.
A method for enhancing bone mineral density in a human needing enhancement of bone density, consisting essentially of administering to said human a human PTH (1-84) pharmaceutical formulation, having a single active agent consisting of a human PTH (1-84), once daily at a PTH (1-84) dose of 50–100 μg as a monotherapy, in combination with vitamin D, in combination with calcium, or in combination with vitamin D and calcium.
A method for treating a post menopausal female human afflicted with osteoporosis to enhance bone mineral density of said human consisting essentially of administering to said human a human PTH (1-84) pharmaceutical formulation, having a single active agent consisting of a human PTH (1-84), by subcutaneous injection once daily at a PTH (1-84) dose of 100 μg for a period of 12 months as a monotherapy, in combination with vitamin D, in combination with calcium, or in combination with vitamin D and calcium.
Dependencies are inferred from the claim text.